Andrew Cittadine - May 29, 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Kim R Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
May 29, 2024
Transactions value $
$23,051
Form type
4
Date filed
5/31/2024, 04:56 PM
Previous filing
May 24, 2024
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Purchase $7.64K +12K +20.82% $0.64 69.6K May 29, 2024 Direct F1
transaction MNPR Common Stock Purchase $7.68K +12K +17.24% $0.64 81.6K May 30, 2024 Direct F2
transaction MNPR Common Stock Purchase $7.73K +12K +14.7% $0.64 93.6K May 31, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.637, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.629 to $0.64, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.61 to $0.6502, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.